United Therapeutics (UTHR) Equity Income (2009 - 2013)

United Therapeutics has disclosed Equity Income across 5 years of filings, most recently posting -$72000.0 for Q2 2013.

• Equity Income for Q2 2013 came in at -$72000.0, down 71.43% year-over-year; the trailing twelve-month figure through Jun 2013 was -$200000.0 (down 75.44% YoY), and the FY2012 annual result was -$143000.0, down 20.17% from the prior year.
• Equity Income came in at -$72000.0 for Q2 2013 at United Therapeutics, down from -$47000.0 in the prior quarter.
• In the past five years, Equity Income ranged from a high of -$9000.0 in Q4 2011 to a low of -$72000.0 in Q2 2013.
• The 5-year median for Equity Income is -$42000.0 (2009), against an average of -$39000.0.
• Across the five-year window, Equity Income surged 70.0% in 2011 and slumped 266.67% in 2012, its largest moves.
• United Therapeutics' Equity Income stood at -$42000.0 in 2009, then increased by 28.57% to -$30000.0 in 2010, then soared by 70.0% to -$9000.0 in 2011, then plunged by 266.67% to -$33000.0 in 2012, then plunged by 118.18% to -$72000.0 in 2013.
• The last three Equity Income figures came in at -$72000.0 (Q2 2013), -$47000.0 (Q1 2013), and -$33000.0 (Q4 2012), per Business Quant data.